Roland Beckmann

USPTO Granted Patents = 15 (Patent Applications = 9)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 2.1

ph-index = 4

Forward Citations = 59(Granted Patents)

Location History:

Vienna, AU (2015)
Vienna, AT (2013 - 2023)
Penzberg, DE (2021 - 2024)

Company Filing History:

Hoffmann-la Roche Inc.

where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11866490 - Antibody that binds to VEGF and IL-1beta and methods of use (2024-01-09),

2. 11732036 - Antibody that binds to VEGF-A and ANG2 and methods of use (2023-08-22),

3. 11542327 - Methods of treating pruritic disease with IL-31 monoclonal antibodies (2023-01-03),

4. 11130804 - Antibody that binds to VEGF and IL-1beta and methods of use (2021-09-28),

5. 10738103 - Antibody light chains (2020-08-11),

6. 10640559 - Nucleic acid molecules encoding humanized IL-31 monoclonal antibodies (2020-05-05),

7. 9982044 - Method of treating pruritus with IL-31 monoclonal antibody formulations (2018-05-29),

8. 9944719 - Dual targeting (2018-04-17),

9. 9738715 - IL-31 monoclonal antibody formulations (2017-08-22),

10. 9708388 - Antibody light chains (2017-07-18),

11. 9416184 - Method of treating pruritus with IL-31 monoclonal antibodies (2016-08-16),

12. 9005921 - Polynucleotides encoding IL-31 monoclonal antibodies (2015-04-14),

13. 8685669 - Nucleic acid molecules encoding humanized antibody molecules specific for IL-31 (2014-04-01),

14. 8545844 - Humanized antibodies against human IL-22RA (2013-10-01),

15. 8470979 - Humanized antibody molecules specific for IL-31 (2013-06-25),

Title: Roland Beckmann: Pioneering Innovator in Vienna

Introduction: Roland Beckmann, a prolific inventor based in Vienna, AT, has made significant strides in the field of biotechnology with a remarkable portfolio of 15 patents to his name. His groundbreaking work at Merck Serono S. A. has garnered widespread acclaim and recognition in the scientific community.

Latest Patents: Beckmann's latest patents showcase his ingenuity and commitment to advancing medical research. The first patent pertains to an antibody that binds to VEGF and IL-1beta, unveiling novel methods for utilizing these antibodies effectively. The second patent introduces an antibody targeting VEGF-A and ANG2, presented in the form of a bispecific Fab fragment, revolutionizing treatment approaches in biopharmaceuticals.

Career Highlights: Beckmann's journey as an inventor has been defined by excellence and innovation. His tenure at Merck Serono S. A. has been marked by a relentless pursuit of scientific discovery and a passion for creating transformative solutions in biomedicine. With 15 patents under his belt, Beckmann continues to push the boundaries of biotechnology with his pioneering research.

Collaborations: Collaborating with esteemed colleagues such as Kent Bondensgaard and Guido Hartmann has been instrumental in Beckmann's success. Together, they have formed a dynamic team that thrives on collaboration, bringing together diverse perspectives and expertise to drive forward groundbreaking projects and achieve remarkable results.

Conclusion: Roland Beckmann's contributions to the field of biotechnology stand as a testament to his innovative spirit and unwavering dedication to scientific exploration. His prolific patent portfolio, coupled with his collaborative ethos, positions him as a trailblazer in the realm of medical research, inspiring future generations of inventors to push the boundaries of what is possible in the world of biopharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.